20-hydroxy-5,8,11,14-eicosatetraenoic acid has been researched along with Brain Vascular Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cseplo, P; Csiszar, A; Koller, A; Sonntag, WE; Sosnowska, D; Springo, Z; Tarantini, S; Toth, P; Tucsek, Z; Ungvari, Z | 1 |
| Balazy, M; Bednar, MM; Falck, JR; Gross, CE | 1 |
2 other study(ies) available for 20-hydroxy-5,8,11,14-eicosatetraenoic acid and Brain Vascular Disorders
| Article | Year |
|---|---|
Treatment with the cytochrome P450 ω-hydroxylase inhibitor HET0016 attenuates cerebrovascular inflammation, oxidative stress and improves vasomotor function in spontaneously hypertensive rats.
Topics: Amidines; Animals; Blood Pressure; Cells, Cultured; Cerebrovascular Disorders; Cytochrome P-450 Enzyme System; Cytokines; Hydroxyeicosatetraenoic Acids; Male; Middle Cerebral Artery; NF-kappa B; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Vasomotor System | 2013 |
Antineutrophil strategies.
Topics: Aged; Aged, 80 and over; Brain Ischemia; Cell Adhesion; Cerebrovascular Disorders; Humans; Hydroxyeicosatetraenoic Acids; Leukocyte Count; Middle Aged; Neutrophil Activation; Neutrophils | 1997 |